The cannabis industry has been notoriously successful over the course of the past few years, but new innovation in the space and the changing public perception of cannabis have all contributed to the market growing even larger in the past several months. Many companies have risen to the forefront of the industry by offering new products and new types of medicines across the board.
One of the stocks that many investors have been watching and one that should come as no surprise is the company Cronos Group (TSX:CRON). The company was one of the first cannabis stocks to be listed on a U.S. exchange which brought them a large amount of notoriety back in the beginning of the year. According to one report “Cronos Group owns and operates two licensed producers of medical marijuana in Canada: Peace Naturals and Original BC. Cronos plans to ramp up production at its Peace Naturals facility from the existing 5,000 kg to 40,000 kg before 2019.” The hopes are that the company can continue to ramp up its production as they move into the international space as well. Cronos has also been working to set up a low-cost factory for producing cannabis in Israel, which can potentially help with any concerns on overproduction that investors may have feared earlier in the companies history. With a market cap of around $1.5 billion, it seems as though the Cronos Group is here to stay.
The next company on the list is one of the smaller guys in the business, but one that many investors have been keen on watching. GT Biopharma Inc ( GTBP ) as the company states, is a “biotechnology company focused on innovative drugs for the treatment of cancer. GT’s most advanced oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific recombinant fusion protein-drug conjugate targeting CD19 and CD22 on lymphoma and leukemia cells with a modified form of diphtheria toxin as its cytotoxic dru payload. OXS-1550 targets cancer cells expressing the CD19 receptor or the CD22 receptor or both receptors.” The company has been working at the forefront of the cannabis space to help produce new and innovative drugs in such a cutting edge market. As they work to create new cures and treatments for various aspects and types of cancer, it seems as though they are poised perfectly throughout the industry to take advantage of the new and growing market.
The cannabis industry has been notoriously successful over the course of the past few months to years. The hopes are high that companies like the ones mentioned above can continue to provide a new basis for growth in the market, and innovation further down the road. Only time will tell how well these companies can continue to perform amidst rampant competition and the changing public tide on cannabis as a whole.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
